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Cellular repopulation of human vein
allograft bypass grafts
Todd R. Johnson, BA, John E. Tomaszewski, MD, and Jeffrey P. Carpenter,
MD, Philadelphia, Pa 
Purpose: Vein allografts are an alternative conduit for patients lacking available auto-
genous vein. The ability to develop a neoendothelium is a potential advantage of
allografts over other nonautogenous grafts, because endothelial cells have been
shown to play numerous essential roles in vessel survival. However, repopulation by
endothelial cells has not previously been demonstrated or characterized in human
subjects.
Methods: In our prospective trial, 40 patients (20 men, 20 women) underwent cryo-
preserved saphenous vein bypass grafting procedures for limb salvage. Several
patients underwent multiple grafting procedures. All grafts were sampled at implan-
tation. During the 31 month follow-up interval, 22 allografts were explanted at the
time of revision or subsequent surgical procedure. All grafts (22 of 22) demonstrat-
ed intact endothelium at implantation and explantation. Seventeen explantation
biopsy samples (seven from men, 10 from women) from 16 patients (seven men, nine
women) were adequate for further histologic and immunofluorescent analysis.
Explants were stained with hematoxylin-eosin and immunohistochemical markers to
quantitate rejection and also underwent fluorescence in-situ hybridization, with
probes for X and Y chromosomes and counterstain for nuclear envelope. Cells were
counted as XX, XY, XO, YO, or unstained. The endothelium and vessel walls were
analyzed for origin of cells based on sex-mismatched transplants, with sex-matched
transplants serving as controls.
Results: Evidence of cellular damage was noted in all explanted allografts, and mod-
erate or severe rejection (lymphocyte infiltrate, +CD3, +CD8, +CR3, cytotoxic gran-
ules) was noted in six explanted allografts (29%). All allografts demonstrated intact
endothelium (complete or partial), at the time of both implantation and explanta-
tion. Sex-matched (male to male) control explants showed only male cells, as expect-
ed. Male donor–female recipient transplants showed complete repopulation by recip-
ient (female) cells in nine of 10 cases (90%), whereas one case (10%) demonstrated
partial repopulation (a mosaic of male and female cells). One patient’s slides were
unreadable. Findings in cells of the allograft wall were identical to those of the
endothelium (nine recipient-only cells and one mosaic). Complete absence of donor
cells was noted as early as 1 week after implantation, but mosaicism was demon-
strated in one patient 3 months after grafting. No relationship could be demon-
strated between repopulation and time (P > .05), quantity of rejection (P > .05), or
donor age (P > .05).
Conclusion: Both the endothelial lining and vessel wall of venous allografts repopulate
with cells of recipient origin, resulting in either a completely novel cellular con-
stituency or a mosaic of host and donor cells. The loss of donor cells may be mediat-
ed by apoptosis or rejection, and the rate of migration of repopulating host cells is, at
this point, unclear. Although the development of a completely endothelial-lined con-
duit offers a potential advantage over other alternative conduits, the functional status
of the neoendothelium and repopulated vessel wall and their role in maintenance of
allograft patency require further investigation. (J Vasc Surg 2000;31:994-1002.)
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Autogenous vein grafts are universally accepted
as the conduit of choice for lower-extremity bypass
grafting procedures. However, these veins are often
unavailable, because they were used in an earlier
bypass grafting procedure or were removed by strip-
ping, creating the need for an alternative. Results
with synthetic materials for such procedures have
been disappointing.1 Consequently, allograft and
xenograft veins would present attractive substitutes,
because they are more readily accessible and offer
the advantage of a human endothelium-lined bio-
logical conduit.
The experimental use of vein allografts has also
been disappointing, demonstrating that they are
subject to frequent and early failure, the causes of
which may include local injury, hypercoagulability,
stasis, and host immune response. In an earlier
paper,2 we demonstrated a strong cell-mediated
immune response to venous allografts in human
subjects. This response was characterized as pre-
dominantly activated T lymphocytes (+CD3, CD8,
CR3) containing cytotoxic granules (TIA-1).
Presence of these cells correlated with vessel-wall
destruction, measured by means of mural hemor-
rhage and necrosis (Table I). Intimal thickening
also occurred in response to injury, and capillary
ingrowth furthered the progression of the immune
response against the grafts.
T lymphocytes involved in this phenomenon
were largely CD8+, suggesting a major histocom-
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patibility complex (MHC) class I-restricted direct
immune response, instead of an indirect response
through MHC class II and antigen presenting cells.
In addition to this class I-restricted response, it has
been suggested that endothelial cells may upregulate
their production of MHC class II and provide an
indirect immune response. In our earlier study, we
found that the quantity of endothelial markers
(CD31, factor VIII) decreased with time and the
rejection response, perhaps because of donor
endothelial cell destruction (Table I). Endothelial
markers also declined with the duration of graft
patency. The loss of endothelium also correlated
with an increase in intimal thickening and an
increase in activated CD8 T cell infiltrate. It is
unclear whether these observations provide evidence
of an endothelial role in facilitating or retarding the
rejection response. 
These correlations suggest that endothelial cells,
regardless of their loyalty, may play an important
role in the allograft tolerance and rejection process-
es. It is thus essential that we further our under-
standing of such interactions. We sought to charac-
terize the origin of the endothelial cells in our
explanted grafts, with the hypothesis that posttrans-
plantation repopulation of the endothelium of such
allografts may occur. Repopulation of the allograft
endothelium by host cells may initially expedite an
immune response, or it may suppress this response
and thereby decrease transplant failure rates. We
Table I. Significant correlations (p < 0.05) between markers for 22 explanted allografts*
Variable Positive Correlation Negative Correlation
Graft patency duration — Factor VIII, CD31
Azathioprine immunosuppression — TIA-1
Cellular infiltrate Capillary ingrowth, LCA, CD3, CD8, CR3 —
Mural hemorrhage Intimal thickening, TIA-1 —
Medial necrosis Intimal thickening, TIA-1 —
Capillary ingrowth Cellular infiltrate, LCA, CD3, CD8, CR3, CD31, factor VIII —
Intimal thickening Mural hemorrhage, mural necrosis TIA-1, factor VIII
LCA Cellular infiltrate, capillary ingrowth, CD3, CR3, CD31, —
factor VIII
CD3 Cellular infiltrate, capillary ingrowth, LCA, CR3 SMA
CD8 Cellular infiltrate, capillary ingrowth, TIA-1, factor VIII —
CR3 Capillary ingrowth, LCA, CD3, CD31, factor VIII —
TIA-1 Mural hemorrhage, mural necrosis, CD8 Intimal thickening, 
azathioprine immuno-
suppression
SMA — CD3
CD31 Cellular infiltrate, capillary ingrowth, CD56, factor VIII, Graft patency duration
LCA, CD3
Factor VIII Capillary ingrowth, LCA, CD8, CR3, CD31 Intimal thickening, graft
patency duration
*No significant correlations were identified for CD30, CD79, L-26, CD35, or CD56.
Reprinted from the J Vasc Surg.
observed repopulation of both endothelial cells and
cells of the medial vessel wall in human venous allo-
grafts and attempted to correlate such repopulation
with time, severity of rejection, and donor age.
MATERIAL AND METHODS
Trial design. In the context of a prospective trial
approved by the Human Subjects Committee of the
University of Pennsylvania, 20 male and 20 female
patients with rest pain and/or tissue loss requiring
bypass grafting to pedal or crural outflow and lack-
ing adequate autogenous saphenous vein were ran-
domly assigned to receive (17 patients) or not
receive (23 patients) azathioprine (1 mg/kg per
day) after cryopreserved vein allograft bypass graft-
ing. 
Venous allografts. Cryopreserved saphenous
vein allografts were obtained from Cryolife
Cardiovascular (Marietta, Ga). Veins were stored in
a dimethyl sufoxide solution at –196°C. Single-
donor veins only (no composite allografts) were
used. All grafts were larger than 4 mm in diameter
and were ABO blood group matched to the recipi-
ent. Grafts were not HLA-matched, because this
technique is not feasible in clinical applications
because of limited graft availability. All patients
underwent biopsies of the allografts at the time of
implantation. Twenty-two patients underwent biop-
sies of previously implanted allografts at the time of
subsequent graft revision or amputation. For
patients whose biopsies were performed from
thrombosed grafts at the time of subsequent ampu-
tation (16 patients), specimens were taken from the
juxta-anastomotic region to obtain a portion of graft
from the patent “stump.” For patients who were
undergoing graft revision for repair of a stenosis or
excision of a graft aneurysm, patent midgraft speci-
mens were obtained (six patients). Biopsies were
fixed in paraffin and stored at 25°C. Further studies
were carried out on 17 of these biopsies (in seven
men and 10 women); five were unfit for further
analysis.
Histologic analysis. Standard hematoxylin and
eosin preparations were made of implanted and
explanted allografts. Paraffin immunohistochemistry
study was performed with the standard avidin-biotin
complex technique, capillary gap technology, and a
robotic immunostainer (Ventanna-Biotek, Tucson,
Ariz). One pathologist (J.E.T.) evaluated hema-
toxylin and eosin and immunostained slides in a
semiquantitative manner. Each explanted graft was
tested with antibodies against smooth muscle actin
(SMA), CD3, and TIA-1 (DAKO, Carpenteria,
Calif). Each graft was also stained with antibodies
against factor VIII (DAKO) to quantify the presence
of intact endothelium. Scoring was performed
according to these criteria: 0, no label and no
change; 1+, less than 2% of compartment labeled or
affected by feature; 2+, 3% to 10% of compartment
labeled or affected by feature; 3+, moderate, 11% to
50% of compartment labeled or affected by feature;
4+, heavy or severe, more than 50% of compartment
labeled or affected by feature.
Immunofluorescent analysis. Slides of each
allograft biopsy were prepared according to stan-
dard protocol, as were slides of human ovary and
prostate for use as controls. Directly before use,
slides were soaked in 100% xylenes to remove fixa-
tive and then washed in 100% ethanol. Slides were
then rehydrated with ethanol and pretreated in 30%
sodium bisulfate at 72°C for 30 minutes. Tissues
were digested in proteinase K (Boehringer
Mannheim, 1:3000 in TE buffer), at 37°C for 1
hour. SO CEP X and SG CEP Y (SpectrumOrange
Chromosome Enumeration Probe X and Spectrum
Green Chromosome Enumeration Probe Y) dual
color complementary DNA probes (Vysis, Downers
Grove, Ill) were diluted 1 to 10 in CEP hybridiza-
tion buffer (Vysis). CEP X (alpha satellite)
SpectrumOrange hybridizes to the centromere of
human chromosome X (bands p11.1 to q11, locus
DXZ1), and CEP Y SpectrumGreen to the satellite
III sequence of human chromosome Y (band Yq12,
locus DYZ1). Probe solutions were denatured in
70% formamide at 73°C for 5 minutes. Slides were
removed from proteinase K, and also denatured in
70% formamide at 73°C for 5 minutes. Denatured
slides were dehydrated in serial ethanol dilutions
and air-dried. Each slide received 10 µL of probe
solution. Hybridization took place overnight in a
humidified chamber at 42°C. After hybridization,
slides were washed in 2x SSC, and then counter-
stained with 10 µL 4,6-diamidino-2-phenylindole/
antifade before microscopy.
Microscopic assessment of allograft repopula-
tion. All stained slides were read with a 
single trichrome lens (Chroma Technologies
DAPI/FITC/Texas Red) by a single investigator
(T.R.J.) and analyzed for the presence of specific
nuclear staining. One hundred cells (roughly one
tenth of the total number of cells per slide) were
assessed from each slide from the endothelium and
medial vessel wall. Endothelium and media were
each analyzed separately. Adventitia was not ana-
lyzed because of the injury to that layer, which may
have been caused by the ingrowth of donor cells and
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matrix components, and subsequent injury on
explantation. The nucleus of each cell was counted
for the number of red or green signals and recorded
as either XX, XY, XO, YO, or unstained. The inves-
tigator was blinded to both donor and recipient sex
status for each slide. Data were compiled and sepa-
rated between female and male recipients (all allo-
graft donors were men). Data were analyzed by
using Statview statistical software (ABACUS
Concepts, Berkeley, Calif) to calculate the Pearson
correlation coefficient.
RESULTS
Clinical results of the trial were reported previ-
ously.3
Histologic analysis. All allografts (17 of 17)
demonstrated intact endothelium (complete or par-
tial) both at the time of implantation and explanta-
tion, as assessed by means of intimal staining with
antibodies to factor VIII. All biopsies except one (16
of 17) demonstrated intact smooth muscle cells, as
measured by means of anti-SMA antibody staining
within the media of vessel walls. All biopsies (17 of
17) demonstrated cells morphologically consistent
with smooth muscle cells populating the media. 
Evidence of cellular damage was noted in all
explanted allografts, and moderate or severe rejec-
tion (lymphocyte infiltrate, +CD3, and TIA-1) was
noted in six explanted allografts (29%). Further
studies characterizing the cellular infiltrate of these
grafts have been previously published by the
authors2 and are summarized in the introduction
and presented in Table I.
Immunohistochemical analysis. A biopsy of 17
allografts was performed posttransplantation at the
time of thrombosis, revision, or subsequent surgical
Fig 1. Endothelial repopulation of male donor (XY) saphenous vein allograft by cells from
female recipient (XX). The cells are shown at high power (100× with oil) under fluorescence
microscopy. The cell at the top of the field (arrow) clearly demonstrates two X chromosomes
(red) within the nucleus (blue), denoting female genotype. No cells in the graft stained for the
Y chromosome (green), whereas 60% stained for XX genotype, 20% stained for single X chro-
mosome only (XO), and 20% did not stain (OO). The three-dimensional orientation of chro-
mosomes in the nucleus caused considerable difficulty in simultaneously photographing both
chromosomes, accounting for the apparent lack of staining of all cells in this field.
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procedure. All allografts were from male donors. A
biopsy of seven allografts from male recipients (con-
trols) was performed. There was a biopsy of 10 allo-
grafts from female recipients. The endothelia of all
male-to-male allografts were populated with more
than 80% male cells (XY; small numbers of XX-stain-
ing nuclei were present in male-to-male grafts, which
most likely represent X staining abnormalities or the
loss of Y chromosome because of tissue digestion).
Similarly, the vessels walls (media and adventitia) of
all male-to-male allografts were populated with more
than 80% male cells. In contrast, the endothelia of
nine male-to-female allografts were populated by
more than 54% female cells (XX; Fig 1). These nine
allografts showed no Y chromosome-positive nuclei.
The endothelium of one male-to-female allograft was
populated with a mosaic of male and female cells,
reporting 40% to 50% of cells as male and 30% to 35%
of cells as female (20% to 30% of cells noninforma-
tive, XO; Fig 2). Similarly, the vessel walls of nine
male-to-female allografts were populated almost
entirely by female cells (XX; Fig 3). The vessel walls
of one male-to-female allograft were populated by a
mosaic of 36% to 39% male cells and 22% to 26%
female cells, with 22% to 26% of cells noninformative
(Fig 4 ). One female patient’s slides were unreadable.
Cells repopulating the media and adventitia were
morphologically consistent with smooth muscle cells,
and slides from adjacent regions of each biopsy
stained consistently for SMA. Most cells demonstrat-
ed an elongated “cigar-like” shape. All were mononu-
clear and did not appear to be inflammatory cells.
Further specific immunohistochemical staining to
determine histologic cell type could not be per-
formed, because of technological limitations.
The complete absence of donor cells was noted
as early as 1 week after implantation, but mosaicism
was demonstrated in one patient 3 months after
grafting. No relationship could be demonstrated
between repopulation and time (P > .05), quantity
of rejection (P > .05), or donor age (P > .05). Of the
20 grafts for which data are presented, six grafts
were given immunosuppression (four female, two
male). No relation was found between the receipt of
Fig 2. Endothelial cells from a male donor allograft into a female recipient demonstrate
mosaicism. The cells are shown at high power (100× with oil) under fluorescence microscopy.
The cell at the top of the field (straight arrow) stains for X (red) and Y (green) chromosomes
within the nucleus (blue), denoting male genotype. The cell at the bottom of the field (curved
arrow) stains for two X chromosomes, denoting female genotype. 
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immunosuppression and the degree of cellular
repopulation.
DISCUSSION
Since Alexis Carrel successfully performed vascu-
lar transplantation in the early part of this century,4
the search for an ideal vascular graft has continued.
Autologous vein has remained the conduit of choice
for small vessel procedures.5 Prosthetic grafts to
small vessels perform poorly,6,7 generating interest
in allografts as a biological alternative to prosthetic
material. The presence of an endothelial lining in an
allograft poses a theoretical advantage over prosthet-
ic alternative grafts; however, venous allografts have
demonstrated a low success rate,8-14 associated with
rejection by the host immune system.2
Allograft endothelium has been postulated to
play a number of important roles in graft survival.
An intact endothelium may help to preserve graft
integrity, because the expression of prostacyclin
inhibits immune cell attachment and diapedesis
through the vessel wall. Furthermore, damage to the
endothelium allows subsequent exposure of colla-
gen, which is highly immunogenic and a natural site
for white blood cell attachment.15 Endothelium also
provides essential functions in intragraft intercellular
signaling, mediating dilatation and constriction in
response to nitric oxide, hormones, and local blood
pressures. 
Endothelial cells may also play a role in allograft
destruction. These cells may be induced to express
MHC class II and can thus function as antigen-pre-
senting cells, expediting rejection by the host
immune system. The balance of these functions and
their interactions with neighboring cells and the
immune system may determine allograft survival.
Initially, venous allografts were hypothesized to
be less immunogenic than other allograft tissues.16
The present study in humans and earlier animal
investigations by Perloff et al, Thiede et al, and
Fig 3. Complete repopulation of the medial compartment of male donor allograft vessel wall
by female recipient cells. The cells are shown at high power (100× with oil) under fluorescence
microscopy. The cells pictured reside in the media. All cells except one demonstrate staining of
two X chromosomes (red) within the nucleus (blue), suggesting the complete replacement of
male cells. No cells in the graft stained for the Y chromosome.
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Axthelm et al demonstrate that this is not the
case.17-19 We found evidence of cellular damage in
all explanted allografts. Venous allografts undergo
transplantation rejection much like any other organ.
When a graft is placed, an early inflammatory reac-
tion occurs, which causes sloughing of endothelial
cells. Such endothelial sloughing exposes the
smooth muscle and fibrous tissue of the inner elastic
lamina, creating a surface on which host white blood
cells and other immune mediators attach and pene-
trate. This allows host immune recognition of the
inner-wall elements and elicits both humoral and
cell-mediated immune responses. The strong arm of
this response is activated cytotoxic CD8+ T lympho-
cytes, which can cause direct cellular damage by
inducing apoptosis and indirect damage by the
release of cytokines that provoke further immune
response and inflammation. With time, capillary
ingrowth and intimal thickening occur, easing the
delivery of mediators and increasing graft injury.
The combination of these factors may lead to local
injury, thrombogenesis, and, finally, graft
occlusion.2,20
Cryopreservation has also been suggested to
maintain cellular viability and structural integrity of
allografts and perhaps to desensitize the immuno-
logic response to transplantation.21 Cryopre-
servation and thawing have been shown to result in
functional endothelial and smooth muscle cells.3
Our grafts demonstrated some evidence of injury to
the smooth muscle outer layers, but the innermost
smooth muscle and endothelium were intact both
before implantation and after explantation.
Whether viable cells are even necessary in cryo-
preserved allografts is questionable, because they
may function simply as a matrix on which ingrowth
of host cells may occur.22 Further research will be
necessary to determine whether the neoendothelium
and repopulated smooth muscle cells are actually
functional and whether their function favors patency
(anticoagulation) or thrombosis.
This study demonstrates graft damage and a cel-
lular immune infiltrate in grafts concomitant with
repopulation of cells in both the endothelial layer
and within the vessel wall. Our study used immuno-
fluorescence techniques as a means of demonstrating
Fig 4. Mosaic repopulation of the medial compartment of male donor allografts. The cells are
shown at high power (100× with oil) under fluorescence microscopy. The cells pictured reside
in the media. The single S-shaped spindle cell at the top of the picture (straight arrow) stains
two X chromosomes (female). Two cells at the lower border of the picture (curved arrows)
stain single Y chromosomes, suggesting male genotype.
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infiltration of the endothelium and media by donor
endothelial and smooth muscle cells. We postulate
that, during an initial rejection response to the
donor allotype graft, repopulation by host cells
begins to occur, altering the cellular immunotype of
the graft itself. This phenomenon is characterized by
medial necrosis and cellular infiltrates, as shown in
our previous paper2 and summarized in Table I. 
Repopulation by host endothelial and smooth
muscle cells and invasion by host immune cells asso-
ciated with damage and rejection were observed in
slides from the same biopsies and thus represent
concomitant phenomena. We found complete
repopulation of endothelium and smooth muscle by
host cells with similar morphology in 80% of our
allografts. The route of migration of these repopu-
lating host cells is unclear. It is unlikely that cells
simply migrate in from the anastomotic ends of the
vessels, because midgraft specimens and specimens
from juxta-anastomotic locations demonstrate com-
plete repopulation. Partial repopulation (a mosaic of
male and female cells) was observed in one patient.
Complete absence of donor cells was noted as early
as 1 week after implantation, but mosaicism was
demonstrated in one patient 3 months after grafting.
No relationship could be demonstrated between
repopulation and quantity of rejection (P > .05),
donor age (P > .05), or the use of immunosuppres-
sion. The functional significance of mosaicism is not
yet determined. Mosaics may represent heterogene-
ity in the motility of repopulating cells, increased
immunologic compatibility between certain individ-
uals, or heterogeneity in the extent of intercellular
communication between cells of host and graft.
Presumably repopulation by host cells, which we
observed in a number of patients, should decrease
graft antigenicity and thereby significantly attenuate
the host immune response. Such a scenario has been
previously postulated by a number of researchers for
liver, kidney, and bone marrow transplants. In the lat-
ter setting, donor hematopoietic cells have been
shown to reside in a chimeric state with those of host
origin. It has been hypothesized that spontaneous
microchimerism may be essential for development
and maintenance of immunological unresponsiveness
to grafts.23 Confirmation of such a theory could offer
insight into the repopulation of venous allografts.
Furthermore, similar research could lead to strategies
to create an immunologically invisible graft (toler-
ance), obviating the need for immunosuppression.
The functionality of the repopulated graft and its
neoendothelium and the exact mechanism of repopu-
lation are unknown and require further investigation.
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